Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Mutual

Eventide Healthcare & Life Sciences Fund Eventide Healthcare & Life Sciences Fund Class A Shares (ETAHX)

Ticker ETAHX · · Holdings as of Jun 30, 2026

Expense ratio
1.54%$154/yr per $10k
5-yr return
−0.5%annualized
1-yr return
+47.4%as of Dec 2025
Net assets
$1.8Ball share classes
Holdings
93

Bottom line

Is ETAHX a good fund? The bottom line

ETAHX is a share class of Eventide Healthcare & Life Sciences Fund, a managed health care sector mutual fund from Mutual.

Annual fees run 1.54% — about $154 a year on every $10,000 invested, more expensive than 82% of health care sector funds we track.

It returned +47.4% over one year, −0.5% a year over five years, +9.9% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.8 billion in net assets and 93 holdings, its largest position is Guardant Health Inc (5.4%) and the top 10 make up 32.4% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.54%)
  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What ETAHX invests in

The Eventide Healthcare & Life Sciences Fund (the Healthcare & Life Sciences Fund or the Fund) seeks to achieve long-term capital appreciation.

Under normal market conditions, the Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies may include private and other companies whose securities may have legal or contractual restrictions on resale or are…

From the fund's prospectus (filed Oct 28, 2026).

ETAHX performance

Fund calendar-year total returns, 2015–2025 2015: +14.9%; 2016: −16.3%; 2017: +45.5%; 2018: −0.4%; 2019: +58.3%; 2020: +36.7%; 2021: −16.8%; 2022: −19.8%; 2023: +10.8%; 2024: −10.4%; 2025: +56.3% +15% 2015 −16% 2016 +46% 2017 −0% 2018 +58% 2019 +37% 2020 −17% 2021 −20% 2022 +11% 2023 −10% 2024 +56% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
ETAHX+47.4%−0.5%+9.9%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full ETAHX performance history →

What ETAHX costs

On a $10,000 investment, ETAHX's 1.54% expense ratio costs about $154 a year. The prospectus estimates $2,304 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full ETAHX fee table →

ETAHX top 10 holdings

#Holding% of fund
1Guardant Health Inc5.37%
2US Bank Mmda3.75%
3Mirum Pharmaceuticals Inc3.47%
4Kymera Therapeutics Inc3.22%
5Abivax Sa2.94%
6BeLite Bio Inc2.83%
7Trevi Therapeutics Inc2.77%
8Mbx Biosciences Inc2.70%
9Vaxcyte Inc2.69%
10Cytokinetics Inc2.69%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 32.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to ETAHX

More funds like ETAHX →

ETAHX FAQ

What is the expense ratio of ETAHX?
ETAHX's expense ratio is 1.54%, which works out to about $154 a year for every $10,000 invested. The prospectus estimates total costs of $2,304 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is ETAHX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.54%); 5-year return in the bottom quarter of its category; front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does ETAHX hold?
ETAHX's largest holdings are Guardant Health Inc (5.4%), US Bank Mmda (3.7%), Mirum Pharmaceuticals Inc (3.5%), Kymera Therapeutics Inc (3.2%), Abivax Sa (2.9%). It holds 93 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is ETAHX's 5-year return?
ETAHX returned −0.5% a year over the five years ending Dec 31, 2025, and +9.9% a year over ten years. Past performance does not guarantee future results.
Does ETAHX have a sales load?
Yes. ETAHX has a maximum front-end sales charge of 5.75%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages ETAHX?
ETAHX is offered by Mutual through Mutual Fund Series Trust.